News & Updates

The final, long-term results from the phase III CheckMate 238 trial continue to show the superior recurrence-free survival (RFS) benefit of adjuvant nivolumab (NIVO) over ipilimumab (IPI) for resected stage IIIB-C or IV melanoma.

In the final overall survival (OS) analysis of the phase III EMBARK trial, the combination of enzalutamide and androgen deprivation therapy (ADT; leuprolide acetate) delivers a significant OS benefit in men with high-risk biochemically recurrent (hrBCR) prostate cancer without evidence of metastases on conventional imaging.

Final overall survival (OS) data analysis from the phase III ALEX study presented at ESMO 2025 indicates alectinib is superior to crizotinib in patients with previously untreated ALK-positive (ALK+) non-small-cell lung cancer (NSCLC).

Faecal immunochemical test (FIT) positive result followed by artificial intelligence (AI)–assisted colonoscopy represents the most cost-effective colorectal cancer (CRC) screening strategy in an Asian population, according to a study from the Chinese University of Hong Kong (CUHK).

An 80-year-old Chinese male, a long-term smoker with no signif­icant medical history, was found to have a right lung mass on a routine chest X-ray in August 2021. A CT scan of the chest revealed a domi­nant right lower lobe mass (3.3 x 2.3 x 2.7 cm) with multiple bilateral lung nodules. CT-guided fine needle aspiration cytology (FNAC) of the right lower lobe mass performed on 2 December 2021 confirmed adeno­carcinoma, while a PET-CT scan on 10 January 2022 showed a right low­er lobe tumour with metastases to the left hilar and mediastinal lymph nodes and both lungs. (Figure 1A) Next-generation sequencing (OncoSnap Nonet) identified MET exon 14 (ME­Tex14) skipping mutation. The pro­grammed death ligand 1 (PD-L1) tumour proportion score (TPS) was 0 percent. The patient was diagnosed with stage IV non-small-cell lung can­cer (NSCLC) harbouring a METex14 skipping mutation. His Eastern Coop­erative Oncology Group performance status (ECOG PS) was 0.